Hightide Therapeutics Inc (HK:2511) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HighTide Therapeutics Inc. has announced the completion of patient enrollment for two Phase III clinical trials of HTD1801, a novel treatment targeting type 2 diabetes mellitus (T2DM). The trials aim to assess the efficacy and safety of the drug in improving glycemic control and other metabolic functions in T2DM patients. HTD1801, the company’s leading drug candidate, is recognized for its potential to provide comprehensive treatment for complex metabolic diseases, and has garnered significant regulatory designations in the US and China.
For further insights into HK:2511 stock, check out TipRanks’ Stock Analysis page.